Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review

Yue,Jing; Xu,Fang; Zhang,Ya; Wen,Jingjing; Zhou,Qiaolin

doi:10.3892/etm.2024.12628

Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review

Authors:
- Jing Yue
- Fang Xu
- Ya Zhang
- Jingjing Wen
- Qiaolin Zhou
View Affiliations

Affiliations: Department of Haematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China
Published online on: June 28, 2024 https://doi.org/10.3892/etm.2024.12628
Article Number: 339
Copyright: © Yue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Light chain deposition disease (LCDD) is a rare, clonal plasma cell proliferative condition. The deposition of nonamyloid monoclonal immunoglobulin light chains predominantly affects the kidneys, which may lead to end‑stage renal disease, eventually requiring renal replacement therapy. The present study reported a rare case of LCDD that was confirmed after renal transplantation. A 49‑year‑old man initially presented with heavy proteinuria, hypoproteinemia, hyperlipidemia and renal insufficiency. The patient was diagnosed with nephrotic syndrome and pathological examination revealed fibrillary glomerulonephritis in 2014. Treatment was started with prednisolone. About 5 years later, the patient began to receive continuous hemodialysis due to worsening serum creatinine levels. Renal allograft transplantation was performed in 2020 and dialysis independence was achieved. Laboratory findings before renal transplantation revealed that serum and urine immunofixation electrophoresis was negative. Allograft kidney biopsy established the pathological diagnosis of LCDD at >1 year after renal transplantation for renal dysfunction. The treatment is challenging due to the lack of generally accepted standard treatment practices. Administration of bortezomib combined with dexamethasone was started. As anemia and renal failure developed progressively, the treatment was switched to anti‑CD38 antibody and continuous hemodialysis was restarted. The best response achieved was hematological partial response and relief of anemia. However, the patient's renal function did not improve and he remains to have end‑stage kidney disease. LCDD is easily missed in cases in which serum and urine immunofixation electrophoresis is negative. Hence, early recognition of LCCD based on kidney biopsy is important. To the best of our knowledge, the use of anti‑CD38 antibody therapy in patients with LCDD is rarely reported. Anti‑CD38 antibody is effective in treating LCDD, but it may not reverse the marked deterioration of renal function.

View Figures

View References

1	Bisht K, Fukao T, Chiron M, Richardson P, Atanackovic D, Chini E, Chng WJ, Van De Velde H and Malavasi F: Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med. 12:20332–20352. 2023.PubMed/NCBI View Article : Google Scholar
2	Arrossi AV, Merzianu M, Farver C, Yuan C, Wang SH, Nakashima MO and Cotta CV: Nodular pulmonary light chain deposition disease: an entity associated with Sjögren syndrome or marginal zone lymphoma. J Clin Pathol. 69:490–496. 2016.PubMed/NCBI View Article : Google Scholar
3	Steward M, Yu JH and Gibbons MA: Sjögren's syndrome as a cause of both lymphoid interstitial pneumonia and light chain deposition disease in a single patient. BMJ Case Rep. 15(e249747)2022.PubMed/NCBI View Article : Google Scholar
4	Aoudia R, Bacha MM, Ounissi M, Gaied H, Jerbi M, Abderrahim E, Abdallah TB and Goucha R: Monoclonal gammopathy of renal significance with light-chain deposition disease in kidney transplantation. Saudi J Kidney Dis Transpl. 30:1161–1165. 2019.PubMed/NCBI View Article : Google Scholar
5	Li W, Liang L, Liao Q, Li Y and Zhou Y: CD38: An important regulator of T cell function. Biomed Pharmacother. 153(113395)2022.PubMed/NCBI View Article : Google Scholar
6	Ye X, Zhao Y, Ma W, Ares I, Martínez M, Lopez-Torres B, Martínez-Larrañaga MR, Wang X, Anadón A and Martínez MA: The potential of CD38 protein as a target for autoimmune diseases. Autoimmun Rev. 22(103289)2023.PubMed/NCBI View Article : Google Scholar
7	Holzer MT, Ruffer N, Huber TB, Kötter I, Ostendorf L and Krusche M: Daratumumab for autoimmune diseases: A systematic review. RMD Open. 9(e003604)2023.PubMed/NCBI View Article : Google Scholar
8	De Novellis D, Fontana R, Giudice V, Serio B and Selleri C: Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: Mechanisms of action and resistance. Int J Mol Sci. 24(645)2022.PubMed/NCBI View Article : Google Scholar
9	Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, Dialoupi I, Migkou M, Roussou M, Kanellias N, et al: Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid. 28:259–266. 2021.PubMed/NCBI View Article : Google Scholar
10	Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, Guido R, Gesualdo L, Specchia G, Merlini G, et al: Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function. Blood Adv. 4:1321–1324. 2020.PubMed/NCBI View Article : Google Scholar
11	Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, et al: The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 15:45–59. 2019.PubMed/NCBI View Article : Google Scholar
12	Kobayashi A, Takeda A, Shinjo H, Iguchi D, Ito C, Okada E, Goto N, Futamura K, Okada M, Hiramitsu T, et al: Light chain deposition disease recurrence in renal allograft after long-term remission. Nephron. 147 (Suppl 1):96–100. 2023.PubMed/NCBI View Article : Google Scholar
13	Li J, Koerner J, Basler M, Brunner T, Kirk CJ and Groettrup M: Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int. 95:611–623. 2019.PubMed/NCBI View Article : Google Scholar
14	Masood A, Ehsan H, Iqbal Q, Salman A and Hashmi H: Treatment of light chain deposition disease: A systematic review. J Hematol. 11:123–130. 2022.PubMed/NCBI View Article : Google Scholar
15	Shimamura Y, Ogawa Y, Takizawa H, Hayashi T and Sakurai Y: Light chain deposition disease diagnosed using computed tomography-guided kidney biopsy. Cureus. 13(e15102)2021.PubMed/NCBI View Article : Google Scholar
16	Tsushima T, Suzuki T, Terao T, Miura D, Narita K, Takeuchi M, Shimuzu A and Matsue K: Light chain deposition disease involving kidney and liver in a patient with IgD myeloma. BMC Nephrol. 22(40)2021.PubMed/NCBI View Article : Google Scholar
17	Heybeli C, Alexander MP, Bentall AJ, Amer H, Buadi FK, Dean PG, Dingli D, Dispenzieri A, El Ters M, Gertz MA, et al: Kidney transplantation in patients with monoclonal gammopathy of renal significance (MGRS)-associated lesions: A case series. Am J Kidney Dis. 79:202–216. 2022.PubMed/NCBI View Article : Google Scholar
18	Nambirajan A, Bhowmik D, Singh G, Agarwal SK and Dinda AK: Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: A diagnostic and therapeutic challenge. Transpl Int. 28:375–379. 2015.PubMed/NCBI View Article : Google Scholar
19	Kuppachi S, Holanda D and Thomas CP: Light chain deposition disease after kidney transplantation with long graft survival: Case report. Transplant Proc. 48:255–258. 2016.PubMed/NCBI View Article : Google Scholar
20	Jimenez-Zepeda VH, Vajpeyi R, John R and Trudel S: Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation. Int J Hematol. 96:125–131. 2012.PubMed/NCBI View Article : Google Scholar
21	Tanenbaum ND, Howell DN, Middleton JP and Spurney RF: Lambda light chain deposition disease in a renal allograft. Transplant Proc. 37:4289–4292. 2005.PubMed/NCBI View Article : Google Scholar
22	Larsen T, Hammer A and Jørgensen KA: Recurrence of light-chain deposition disease after renal transplantation. Scand J Urol Nephrol. 42:187–188. 2008.PubMed/NCBI View Article : Google Scholar
23	Ecder T, Tbakhi A, Braun WE, Tubbs RR, Myles J and McMahon JT: De novo light-chain deposition disease in a cadaver renal allograft. Am J Kidney Dis. 28:461–465. 1996.PubMed/NCBI View Article : Google Scholar
24	Horike K, Takeda A, Otsuka Y, Inaguma D, Goto N, Watarai Y, Uchida K and Morozumi K: A case of recurrent light chain deposition disease after living-related renal transplantation-Detailed process of the recurrence. Clin Transplant. 26 (Suppl 24):64–69. 2012.PubMed/NCBI View Article : Google Scholar
25	Taneda S, Honda K, Horita S, Koyama I, Teraoka S, Oda H and Yamaguchi Y: Light chain deposition disease after renal transplantation. Am J Kidney Dis. 52:621–625. 2008.PubMed/NCBI View Article : Google Scholar
26	Ziogas DC, Kastritis E, Terpos E, Roussou M, Migkou M, Gavriatopoulou M, Spanomichou D, Eleutherakis-Papaiakovou E, Fotiou D, Panagiotidis I, et al: Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk Lymphoma. 58:1832–1839. 2017.PubMed/NCBI View Article : Google Scholar